The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

NCI-Funded Clinical Research In Jeopardy, ASCO Focuses on Value of NCTN Groups 2

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Four Options in Colorectal Cancer

Another practice-changing study—CALGB/SWOG 80405— sought to determine whether there is an optimal first-line treatment for patients with untreated metastatic colorectal cancer without KRAS mutations by comparing chemotherapy plus either bevacizumab or cetuximab.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Trump administration seeks to slash NIH by roughly 40% as 27 institutes and centers are whittled down to eight
NCI to remain intact, but its finances are uncertain; FDA is spared big cuts

Confidential Trump administration budget documents show that the upcoming FY26 Budget Request will radically cut about $50 billion out of the U.S. Department of Health and Human Services, reshuffling agency components, and slashing the number of NIH institutes and centers to just eight. 
By Paul Goldberg

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account